In this Issue:
Cortical thinning in patients with NMOSD
Malignancies after mitoxantrone for MS
TN in patients with MS
Temporal evolution of cortical GM lesions in MS
Rituximab versus fingolimod after natalizumab in MS
Omega-3 PUFA and decreased risk of a FCD
Lymphocytosis as a biomarker of natalizumab efficacy
Oral methylprednisolone pulse treatment in progressive MS
Changes in disability after menopause in MS
Helicobacter pylori infection and MS
Please login below to download this issue (PDF)